Navigation Links
HPV vaccine does not appear to be effective for treating pre-existing HPV infection
Date:8/14/2007

For women with human papillomavirus (HPV) infection, use of the HPV-16/18 vaccine will not accelerate reduction of the virus and should not be used to treat the infection, according to a study in the August 15 issue of JAMA.

HPV vaccines were designed to prevent HPV infection and the development of cervical precancers and cancer. Some research has suggested that HPV vaccines could help clear the virus in women already infected, according to background information in the article.

Allan Hildesheim, Ph.D., of the National Cancer Institute, Bethesda, Md., and colleagues conducted a study to address the question of whether women positive for HPV DNA should be encouraged to receive HPV-16/18 vaccination to induce or accelerate clearance of their infections. The trial was conducted in two provinces of Costa Rica and included 2,189 women age 18 to 25 years who were positive for HPV DNA. Participants were randomly assigned to receive three doses of HPV-16/18 vaccine (n = 1,088) or a control hepatitis A vaccine (n = 1,101) over 6 months.

There was no evidence that HPV vaccination significantly altered rates of viral clearance. At the 6-month visit, rates of clearance were 33.4 percent vs. 31.6 percent for HPV-16/18 among participants who received the HPV vaccine and the control vaccine, respectively. At the 12-month visit, rates of clearance among participants in the HPV group and the control group, respectively, were 48.8 percent vs. 49.8 percent for HPV-16/18.

There was no evidence of vaccine effects with further analysis on selected study entry characteristics reflective of disease extent, including HPV-16/18 antibody results, cytologic results, and HPV viral load. Similarly, no evidence of vaccine effects was observed in analyses stratified by other study entry parameters thought to potentially influence clearance rates and efficacy of the vaccine, including time since sexual initiation, oral contraceptive use, cigarette smoking, and concomitant infection with Chlamydia trachomatis or Neisseria gonorrhoeae.

These findings have important clinical implications. For example, in countries where HPV DNA testing is incorporated in cervical cancer screening and prevention efforts, adult women who have abnormal Papanicolaou test results induced by HPV infection and/or who test positive for an oncogenic HPV type using the clinically available HC2 test might be interested in receiving the HPV vaccine to treat their existent infection, the authors write. our results demonstrate that in women positive for HPV DNA, HPV-16/18 vaccination does not accelerate clearance of the virus and should not be used for purposes of treating prevalent infections. (JAMA. 2007;298(7):743-753. Available pre-embargo to the media at www.jamamedia.org)

Editors Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.


Editorial: HPV VaccinesProphylactic, Not Therapeutic

In an accompanying editorial, Lauri E. Markowitz, M.D., of the Centers for Disease Control and Prevention, Atlanta, comments on the findings of Hildesheim and colleagues.

What are the implications of these data and how do they bear on recommendations" The lack of therapeutic efficacy of the quadrivalent HPV vaccine was considered in deliberations by the Advisory Committee on Immunization Practices (ACIP). These data, along with data demonstrating the high likelihood of acquiring HPV infection soon after onset of sexual activity and data on sexual behavior in the United States, all contributed to recommendations for routine immunization at 11 to 12 years of age. Because the vaccine has no therapeutic efficacy, the greatest effect will be realized if the vaccine is administered before sexual debut, prior to exposure to HPV.

In making the recommendation for this age group, the ACIP also considered safety and immunogenicity data and programmatic issues. While there are safety and immunogenicity data in this age group through 18 months, as well as studies indicating good protection through 5 years after vaccination among older women, as for other new vaccines, data on long-term efficacy are limited. Data on longer-term efficacy will be important, particularly when targeting vaccination of 11- to 12-year-olds. Postlicensure safety monitoring, as done for all vaccines, will also be important.(JAMA. 2007;298(7):805-806. Available pre-embargo to the media at www.jamamedia.org)


'/>"/>
Contact: Brooke Hardison-Wang
301-496-6641
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. New hope for cancer victims – will vaccine cure the deadly bug
4. Vaccine for Alzheimer’s diseas
5. New vaccine helps allergy and asthma patients
6. Man against HIV – new vaccine ready for human trials
7. New vaccine helps allergy and asthma patients
8. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
9. HIV did not arise from polio vaccine
10. Double impact vaccine
11. Health Officials Recommend Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... "I have gout, and I wanted to treat it ... is meant to relieve gout and pain caused by varicose veins. I drank it ... time. It relieved what VA doctors called the worst sinusitis case they'd seen and ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober ... anniversary with the grand opening of the Sober College Robert Pfeifer Memorial Learning ... days, December 2-3, and was attended by an overwhelming amount of alumni, family, ...
(Date:12/9/2016)... New York, NY (PRWEB) , ... December 09, 2016 , ... ... that raises awareness for organ transplantation while encouraging readers to sign up as an ... for a lifesaving organ transplant. , An organ donor can save up to ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... LONDON , Dec. 8, 2016 ... Summary GlobalData,s new report, "Australia Glaucoma ... market data on the Australia Glaucoma Surgery Devices ... US dollars, volume (in units) and average prices ... The report also provides company shares and ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... largest share of the market in 2016 and is ... can be attributed to a large number of surgical ... hold the largest share in the patient temperature management ... such as reducing loss of blood during surgeries, lowering ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
Breaking Medicine Technology: